Biocartis Acquires Philips' Molecular Dx Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Swiss firm Biocartis has acquired from Royal Philips Electronics its technology platform for rapid fully-automated DNA/RNA molecular diagnostic testing, the firms announced today.

Philips said that the platform has been designed for applications in a wide range of patient sample testing, including oncology and infectious diseases. Financial details of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.